Elan Corp, plc (ADR) (NYSE:ELN)

CAPS Rating: 3 out of 5

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

Recs

0
Player Avatar Biotech2010 (87.49) Submitted: 1/26/2010 8:50:26 PM : Outperform Start Price: $7.73 ELN Score: +63.99

@6.77

Featured Broker Partners


Advertisement